account_balance
Investment manager · 13F filer · SEC CIK 1274403
ARCH Venture Management, LLC
Reported value$1.1Bas of Jun 30, 2026
Positions12 3 new, 1 sold out
Top 10 weight99.3%PBLS alone is 16%
FiledAug 1445 days after quarter end
Portfolio · as of Jun 30, 2026
Where the money is
New or addedTrimmedHeld
This fund reports 12 stocks.
PBLSParabilis Medicines Inc
16.0%New
BEAMBeam Therapeutics Inc
14.2%
RAPPRapport Therapeutics Inc
14.1%
SPTXSeaport Therapeutics Inc
12.4%New
ERASErasca Inc
11.8%
VIRVir Biotechnology Inc
11.8%
MAZEMaze Therapeutics Inc
11.2%
LYELLyell Immunopharma Inc
4.1%
GENBGenerate Biomedicines Inc
3.0%
TXG0.8%BOLD0.6%PBLSParabilis Medicines Inc
16.0%New
BEAMBeam Therapeutics Inc
14.2%
RAPPRapport Therapeutics Inc
14.1%
SPTXSeaport Therapeutics Inc
12.4%New
ERAS11.8%VIR11.8%MAZE11.2%LYEL4.1%GENB3.0%Box size is the share of the fund. 13F only covers US-listed stocks, so foreign holdings and short positions are missing.
Show the top 12 as a list
PBLS Parabilis Medicines Inc 16.0% NewBEAM Beam Therapeutics Inc 14.2% HeldRAPP Rapport Therapeutics Inc 14.1% HeldSPTX Seaport Therapeutics Inc 12.4% NewERAS Erasca Inc 11.8% HeldVIR Vir Biotechnology Inc 11.8% HeldMAZE Maze Therapeutics Inc 11.2% HeldLYEL Lyell Immunopharma Inc 4.1% HeldGENB Generate Biomedicines Inc 3.0% HeldTXG 10x Genomics Inc 0.8% HeldBOLD Boundless Bio Inc 0.6% NewGOSS Gossamer Bio Inc 0.1% Held
What changed